CMS Proposed Rule Includes Provisions Aimed at Incentivizing Use of Opioid Alternatives

| Brittany McCullough
Medical equipment, stethoscope, prescription

CMS recently released a 761-page sweeping rule that proposes changes to the Medicare hospital outpatient prospective payment system (OPPS) and ambulatory surgical center (ASC) payment system for CY2019. The rule proposes:

  • Increasing cuts to the 340B Drug Discount Program;
  • Removing communication about pain questions from the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey;
  • Reducing the amount hospitals are paid to be more in alignment with the lower physician reimbursement rate to promote site neutrality, and;
  • Removing certain reporting requirements

Although the rule touches on a variety of topics, one area I’d like to focus on are the proposed changes to packaged items and services to incentivize the use of non-opioid medications for pain management at ASCs.

Packaging refers to the coupling of payment for a variety of related items to encourage hospitals to efficiently manage their resources. In addition, it also “encourages hospitals to effectively negotiate with manufacturers and suppliers to reduce the purchase price of items and services or to explore alternative group purchasing arrangements” as CMS notes in the proposed rule. Packaging has been part of the OPPS since CMS first implemented a prospective payment system in 2000.

So where does the incentivization of non-opioid management treatments come into play?

Well, under current payment rules, CMS provides one bundled payment to hospitals for all surgical supplies including drugs intended for pain management. Under this payment structure, hospitals and ambulatory surgical centers receive the same amount, whether the surgeon administers an opioid or a non-opioid. Given the ongoing opioid epidemic, CMS felt cause to examine if their payment policy may in fact encourage the use of opioids. Under the OPPS, they didn’t find any concrete evidence to support this, but, this was not the case for ASCs.

Why is that you ask? Well to be frank, ASCs aren’t necessarily receiving high payments to begin with. In the proposed rule CMS describes ASCs as only being paid roughly 55 percent of the OPPS rate. As a result, ASCs are a lot more cost sensitive. This is important because opioids are cheap. If I’m an ASC and I’m already receiving less money, am I really going to pay more for a non-opioid treatment for postsurgical pain? Probably not.

To mitigate this, CMS has proposed to unpackage non-opioid pain management drugs as part of surgical supplies when rendered in ASCs in CY 2019. The only packaged non-opioid drug under the OPPS and ASC payment system is Exparel which was initially approved by FDA in 2011 for local administration post-surgery. CMS is seeking comment on if there are other effective non-opioid pain management treatments that potentially need separate payment.

Comments on the proposed rule are due September 24.

Brittany McCullough

Brittany McCullough, Health Policy Associate.

Brittany McCullough, URAC's health policy associate, focuses on tracking and analyzing legislation and regulations of importance to URAC stakeholders. Brittany considers herself an early careerist but most of her policy and research work has been centered on the ACA, Medicaid, CHIP, and mental health. She holds a B.S. in Neuroscience and a Master of Health Administration.

Views, thoughts and opinions expressed in my articles belong solely to me, and not necessarily to my employer.

Add new comment

Comment Policy
We welcome your comments to our blog articles. Comments not relevant to the posted topic, contain profanity, offensive or abusive language, or that attack a person individually, will be deleted. We reserve the right to delete any comments submitted to this blog without notice.
Your Information
These values will only be visible to admins. Only your name and the text of your comment will be displayed.
Your Comment

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Like this article?

We also recommend

Subscribe to The URAC Report